Inspire Medical Systems (INSP) Wells Fargo 2026 MedTech Innovation Spotlight summary
Event summary combining transcript, slides, and related documents.
Wells Fargo 2026 MedTech Innovation Spotlight summary
26 Jun, 2026Coding and reimbursement updates
Clear coding pathways established for Medicare, commercial, and Medicare Advantage, with ongoing education for centers and physicians to ensure reimbursement confidence.
Payment levels for facilities and physicians remain consistent with 2025, with minor variations due to modifiers.
Two of seven Medicare MACs require a -52 modifier, resulting in a 10%-20% reduction in physician payment; others may follow, but tools are in place to adapt.
A new CPT code application was submitted to the AMA for review in September 2026, aiming for implementation by January 2028.
WISeR program implementation in six states is improving, with initial headwinds expected to lessen throughout the year.
Technology and product innovation
Inspire V system launched with closed-loop sensing, improving synchronization of stimulation to 87.1% of breaths and eliminating the need for a respiratory sensor.
SleepSync platform enhancements allow digital prior authorization requests, streamlining administrative processes for centers.
Inspire VI is in development, focusing on auto-activation and sleep detection to further improve therapy adherence.
Remote programming for SleepSync is under development, with no set release date yet.
Clinical evidence and outcomes
ADHERE registry of 5,000 patients shows median Apnea-Hypopnea Index reduction from 32 to 10 and 90% patient satisfaction.
Therapy adherence averages 5.8–6.4 hours per night, with most patients not requiring sleep endoscopy based on new PREDICTOR algorithm.
New data links Inspire therapy to significant reductions in hypoxic burden, correlating with improved cardiovascular health.
Large real-world studies show Inspire associated with lower risk of heart failure, coronary artery disease, and cardiomyopathy compared to CPAP and no treatment.
Latest events from Inspire Medical Systems
- Coding and reimbursement headwinds drive near-term revenue decline, but sequential improvement is expected.INSP
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 revenue rose 1.6% to $204.6M, but net loss widened and guidance was cut on reimbursement headwinds.INSP
Q1 20265 May 2026 - All proposals passed amid strong financial growth, leadership updates, and governance reforms.INSP
AGM 20264 May 2026 - 2025 saw double-digit revenue growth, board declassification plans, and expanded ESG initiatives.INSP
Proxy filing20 Mar 2026 - Key votes include director elections, auditor ratification, and board structure changes.INSP
Proxy filing20 Mar 2026 - Inspire V’s launch, reimbursement clarity, and innovation drive growth amid evolving competition.INSP
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - 2025 saw 14% revenue growth, board declassification proposal, and expanded ESG initiatives.INSP
Proxy Filing9 Mar 2026 - Inspire 5 transition boosts outcomes, efficiency, and growth, with strong clinical and market momentum.INSP
UBS Global Healthcare Conference 202513 Feb 2026 - 2026 guidance shows growth but highlights reimbursement and coding risks after strong 2025.INSP
Q4 202512 Feb 2026